Transcriptomic FHIT(low)/pHER2(high) signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer

INTRODUCTION: In recent decades, the development of immunotherapy and targeted therapies has considerably improved the outcome of non-small cell lung cancer (NSCLC) patients. Despite these impressive clinical benefits, new biomarkers are needed for an accurate stratification of NSCLC patients and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Brisebarre, Audrey, Ancel, Julien, Ponchel, Théophile, Loeffler, Emma, Germain, Adeline, Dalstein, Véronique, Dormoy, Valérian, Durlach, Anne, Delepine, Gonzague, Deslée, Gaëtan, Polette, Myriam, Nawrocki-Raby, Béatrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760670/
https://www.ncbi.nlm.nih.gov/pubmed/36544755
http://dx.doi.org/10.3389/fimmu.2022.1058531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760670/
https://www.ncbi.nlm.nih.gov/pubmed/36544755
http://dx.doi.org/10.3389/fimmu.2022.1058531

Ejemplares similares